TITLE

Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors

AUTHOR(S)
Nishikawa, Masatomo; Miyake, Hideaki; Harada, Ken-ichi; Fujisawa, Masato
PUB. DATE
January 2014
SOURCE
Medical Oncology;Jan2014, Vol. 31 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
93504263

 

Related Articles

  • Renal Cancer. Blick, Christopher; Herndon, Anthony; Masaarane, Mohammad // Current Medical Literature: Urology;2011, Vol. 17 Issue 2, p51 

    The article addresses the importance of cytoreductive nephrectomy (CN) in improving survival of patients with metastatic renal cell carcinoma after a targeted therapy. The inclusion of little-molecule inhibitors like tyrosine kinase and mammalian target of rapamycin inhibitors have complemented...

  • Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature. Syrios, John; Kechagias, Georgios; Tsavaris, Nicolas // Journal of Medical Case Reports;2012, Vol. 6 Issue 1, p303 

    Introduction: In this case series and short review of the literature, we underline the impact of nephrectomy combined with sequential therapy based on cytokines, antiangiogenic factors, and mammalian target of rapamycin inhibitors along with metastasectomy on overall survival and quality of life...

  • RAD001 maintained extension of PFS in renal cell carcinoma.  // Hem/Onc Today;4/10/2009, Vol. 10 Issue 7, p15 

    The article presents findings of a phase-3 trial of the efficacy of oral mammalian target of rapamycin (mTOR) inhibitor RAD001 in patients with metastatic renal cell carcinoma.

  • Expression pattern of autophagy-related markers in non-metastatic clear cell renal cell carcinoma: association with disease recurrence following radical nephrectomy. Nishikawa, Masatomo; Miyake, Hideaki; Liu, Bing; Fujisawa, Masato // Journal of Cancer Research & Clinical Oncology;Sep2015, Vol. 141 Issue 9, p1585 

    Purpose: To evaluate the expression of multiple molecular markers associated with autophagy, a cellular degradation pathway for the clearance of damaged or superfluous proteins and organelles, in clear cell renal cell carcinoma (CCRCC) in order to identify the prognostic significance of these...

  • Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review. Syrios, John; Kechagias, Georgios; Tsavaris, Nicolas // BMC Nephrology;2013, Vol. 14 Issue 1, p1 

    Background: Renal cell carcinoma (RCC) may involve both kidneys. When bilateral nephrectomy is necessary renal replacement therapy is mandatory. Treating such patients with sequential therapy based on cytokines, antiangiogenic factors and mammalian target of rapamycin (mTOR) inhibitors is...

  • Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report.  // Journal of Medical Case Reports;2012, Vol. 6 Issue 1, p115 

    The article presents case report a 43-year-old man with advanced chromophobe renal cell carcinoma. The patient was first treated with the tyrosine kinase inhibitor sunitinib and then with sorafenib and the mammalian target of the rapamycin inhibitor everolimus. It is informed that this is the...

  • Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Yasuda, Yosuke; Saito, Kazutaka; Yuasa, Takeshi; Kitsukawa, Shinichi; Urakami, Shinji; Yamamoto, Shinya; Yonese, Junji; Takahashi, Shunji; Fukui, Iwao // International Journal of Clinical Oncology;Oct2013, Vol. 18 Issue 5, p884 

    Background: C-reactive protein (CRP) was an independent prognostic factor for metastatic renal cell carcinoma in the cytokine era. However, the impact of CRP on the survival of metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors has not yet been investigated....

  • Temsirolimus.  // Reactions Weekly;Jun2014, Vol. 1506 Issue 1, p26 

    An abstract of the article "Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma," by K. Numakura and colleagues is presented.

  • Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients. Voog, Eric; Campillo‐Gimenez, Boris; Elkouri, Claude; Priou, Franck; Rolland, Frederic; Laguerre, Brigitte; Elhannani, Chaza; Merrer, Jacques; Pfister, Christian; Sevin, Emmanuel; L'Haridon, Tifenn; Hasbini, Ali; Moise, Laura; Le Rol, Annick; Malhaire, Jean Pierre; Delva, Remy; Vauléon, Elodie; Cojocarasu, Oana; Deguiral, Philippe; Cumin, Isabelle // International Journal of Cancer;Mar2020, Vol. 146 Issue 6, p1643 

    The treatment landscape in metastatic renal cell carcinoma has changed fundamentally over the last decade by the development of antiangiogenic agents, mammalian target of rapamycin inhibitors and immunotherapy. Outside of the context of a clinical trial, the treatments are used sequentially. We...

  • Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma. Choueiri, Michel; Tannir, Nizar; Jonasch, Eric // Current Clinical Pharmacology;Aug2011, Vol. 6 Issue 3, p144 

    Nephrectomy continues to be the cornerstone of treatment for localized renal cell carcinoma (RCC). Despite undergoing nephrectomy, recurrence of disease remains a concern in many patients, and different medical therapies are being investigated as means to decrease this risk. The use of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics